Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
REPL
#3829
Replimune Group, Inc.
1.8
1
USD
+6.47%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+6.47%
Monthly Change
-75.74%
6 month change
-58.49%
Year Change
-75.47%
Previous Close
1.7
0
Open
1.7
3
Bid
Ask
Low
1.6
7
High
1.8
3
Volume
1 454
Markets
US Stock Market
Healthcare
REPL
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
46.61 M
49.07 M
57.78 M
61.42 M
77.09 M
—
Valuation ratios
Enterprise value
1.26 B
727.26 M
907.89 M
450.02 M
691.11 M
2.38 B
Price to earnings ratio
—
-7.51
-5.91
-2.39
-3.18
-10.08
Price to sales ratio
—
—
-181.12
667.43
3 907.96
2 820.96
Price to cash flow ratio
—
-10.79
-8.03
-2.77
-4.09
-12.17
Price to book ratio
—
2.16
1.85
1.37
1.89
3.3
Enterprise value to EBITDA ratio
-15.66
-6.26
-4.85
-1.73
-2.48
-7.46
Profitability ratios
Return on assets %
-0.15
-0.26
-0.27
-0.44
-0.45
-0.75
Return on equity %
-0.16
-0.29
-0.31
-0.58
-0.59
-1.09
Return on invested capital %
-485.28
-709.53
-1 045.41
-1 313
-1 367.48
-1 608.74
Gross margin %
100
—
100
100
100
400
Operating margin %
8 757.39
—
3 119.8
-30.45 K
-130.16 K
-14.25 K
EBITDA margin %
8 669.99
—
3 176.69
-30.01 K
-128.32 K
-13.69 K
Net margin %
8 857.61
—
3 070.54
-27.99 K
-123.03 K
-14.09 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
33.25
19.46
17.52
10.72
7.95
26.8
Inventory turnover
—
—
—
—
—
—
Asset turnover
-0
0
-0.01
0
0
0
Solvency ratios
Debt to assets ratio
0.03
—
0.05
0.1
0.09
0.49
Debt to equity ratio
0.03
—
0.06
0.13
0.12
0.71
Long term debt to total assets ratio
0.02
—
0.04
0.09
0.08
0.45
Long term debt to total equity ratio
0.02
—
0.05
0.12
0.11
0.66
Per share metrics
Operating cash flow per share
—
-1.57
-2.2
-2.79
-2.39
-3.11
EBIT per share
—
-2.27
-3.14
-3.52
-3.24
-3.65
EBITDA per share
—
-2.22
-3.1
-3.48
-3.2
-3.61
Total debt per share
—
—
0.59
0.75
0.63
2.3
Cash per share
—
7.58
10.02
6.32
6.01
16.85
Net current asset value per share
—
7.74
10.18
6.51
6.16
17.34
Tangible book value per share
—
7.88
9.54
5.63
5.16
13.99
Working capital per share
—
7.34
9.6
5.91
5.38
14.8
Book value per share
—
7.88
9.54
5.63
5.16
13.99
News
Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)
FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)